PC
CLDX icon

Polar Capital’s Celldex Therapeutics CLDX Stock Holding History

Polar Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$18.5M Buy
+1,250,000
New +$14.6M 0.14% 140
2015
Q2 		– Sell
-1,304
Closed -$545K – 292
2015
Q1 		$545K Buy
+1,304
New +$466K 0.01% 266
2014
Q4 		– Sell
-946
Closed -$184K – 280
2014
Q3 		$184K Buy
+946
New +$206K ﹤0.01% 268

Other funds holding CLDX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Polar Capital's CLDX Position: Q3 2020 in Review

Polar Capital opened a new position in Celldex Therapeutics (CLDX) in Q3 2020: 1,250,000 shares worth $18.5M. The stake represents 0.14% of the portfolio and ranks #140 among its holdings. This is a return to the name: Polar Capital previously reported a position in CLDX as recently as Q1 2015.

Polar Capital first reported a position in CLDX in Q3 2014 and has held it in 3 quarters since. 91 funds tracked by Wall St. Rank hold CLDX as of Q3 2020.

  • Polar Capital held 1,250,000 shares of Celldex Therapeutics worth $18.5M as of Q3 2020.
  • Celldex Therapeutics was a new Polar Capital position in Q3 2020.
  • Celldex Therapeutics made up 0.14% of Polar Capital's portfolio in Q3 2020, its #140 holding.
  • Polar Capital first reported a position in Celldex Therapeutics in Q3 2014 and has held it in 3 quarters since.
  • 91 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.